Pulmonary sarcoid-like granulomatosis induced by ipilimumab

Journal of Clinical Oncology

Volumn 30, Issue 17, 2012, Pages

  Berthod, Grégoire ^a   Lazor, Romain ^a   Letovanec, Igor ^a   Romano, Emanuela ^a   Noirez, Leslie ^a   Stalder, Jessica Mazza ^a   Speiser, Daniel E ^b   Peters, Solange ^a   Michielin, Olivier ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; IPILIMUMAB; PREDNISONE;

ADULT; ARTICLE; BRAIN METASTASIS; BRONCHUS BIOPSY; CANCER STAGING; CASE REPORT; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; GRANULOMATOSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER METASTASIS; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG SARCOIDOSIS; MALE; MELANOMA; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; GRANULOMA; HUMANS; IMMUNOTHERAPY; LUNG; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SARCOIDOSIS, PULMONARY; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84863938356     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.3298     Document Type: Article

References (22)

1. Miller AJ, Mihm MC Jr: Melanoma. N Engl J Med 355:51-65, 2006
2. Garbe C, Eigentler TK, Keilholz U, et al: Systematic review of medical treatment in melanoma: Current status and future prospects. Oncologist 16:5-24, 2011
3. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
4. Halama N, Zoernig I, Jaeger D: Advanced malignant melanoma: Immunologic and multimodal therapeutic strategies. J Oncol 2010:689893, 2010
5. Leach DR, Krummel MF, Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-1736, 1996 (Pubitemid 26102823)
6. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
7. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526, 2011
8. Downey SG, Klapper JA, Smith FO, et al: Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTLassociated antigen-4 blockade. Clin Cancer Res 13:6681-6688, 2007 (Pubitemid 350206804)
9. Eckert A, Schoeffler A, Dalle S, et al: Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology 218:69-70, 2009
10. Iannuzzi MC, Fontana JR: Sarcoidosis: Clinical presentation, immunopathogenesis, and therapeutics. JAMA 305:391-399, 2011
11. Wolchok JD, Neyns B, Linette G, et al: Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:155-164, 2010
12. Ku GY, Yuan J, Page DB, et al: Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: Lymphocyte count after 2 doses correlates with survival. Cancer 116:1767-1775, 2010
13. Maker AV, Attia P, Rosenberg SA: Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 175:7746-7754, 2005 (Pubitemid 41713475)
14. Pedicord VA, Montalvo W, Leiner IM, et al: Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc Natl Acad Sci U S A 108:266-271, 2011
15. Yuan J, Gnjatic S, Li H, et al: CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 105:20410-20415, 2008
16. Wolchok JD, Saenger Y: The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 13:2-9, 2008 (suppl 4)
17. Hodi FS, Butler M, Oble DA, et al: Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 105:3005-3010, 2008 (Pubitemid 351723658)
18. Phan GQ, Yang JC, Sherry RM, et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372-8377, 2003 (Pubitemid 36842552)
19. Hodi FS, Mihm MC, Soiffer RJ, et al: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 100:4712-4717, 2003 (Pubitemid 36457795)
20. Jaber SH, Cowen EW, Haworth LR, et al: Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch Dermatol 142:166-172, 2006 (Pubitemid 43276528)
21. Berman D, Parker SM, Siegel J, et al: Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 10:11, 2010
22. Heinzerling LM, Anliker MD, Muller J, et al: Sarcoidosis induced by interferon-alpha in melanoma patients: Incidence, clinical manifestations, and management strategies. J Immunother 33:834-839, 2010